T Cells Share Info About Foes Researchers from the University of California at San Francisco discovered that immune cells can communicate the presence of infection with each other, somewhat like honeybees communication about sugar sources. The

San Francisco) National Institute of Allergy and Infectious Diseases $0.6 Two-year grant To further develop its targetable bactericidal proteins against Clostridium difficile bacteria 10/2/12 Cellerant Therapeutics Inc. (San Carlos, Calif.) National Cancer Institute $1.7B SBIR Phase I contract and Phase II option To fund the development of CLT-009 to treat thrombocytopenia in cancer patients 10/9/12 Colby Pharmaceutical Co. (San Jose, Calif.) National Cancer Institute ND SBIR grant For work on

Hyperion Therapeutics Inc., of South San Francisco, completed its follow-on offering of about 2.8 million shares of common stock

Presidio Pharmaceuticals Inc., of San Francisco, said it entered a nonexclusive collaboration with Boehringer Ingelheim GmbH, of Ingelheim, Germany, for a Phase IIa trial testing an interferon-free, all-oral, direct-acting antiviral combination treatment for patients with hepatitis C virus (HCV) infection

Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus, when other alternatives are not suitable...Kadcyla is marketed by Roche AG unit Genentech Inc., of South San Francisco

Inc., of Whitehouse Station, N.J., said researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of Tredaptive (extended-release niacin/laropiprant) during the late-breaking clinical trial session at the American College of Cardiology 62nd Annual Scientific Session in San Francisco...Findings were presented during the late-breaking clinical trial session

Bolstering its news in January, when the firm disclosed that the intravenous antiplatelet cangrelor had proven strong in a Phase III trial as compared to oral clopidogrel, The Medicine Co.'s scientific team offered specifics over the weekend at the American College of Cardiology Scientific Session in San Francisco

Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus, when other alternatives are not suitable

The findings were reported in a late-breaking session at the American College of Cardiology's 62nd Annual Scientific Session in San Francisco and published online in the Journal of the American College of Cardiology

San Francisco) Ravicti Glycerol phenylbutyrate Urea cycle disorders FDA issued an approval 2/4/13 Hemispherx Biopharma Inc. (Philadelphia) Ampligen Rintatolimod Chronic fatigue syndrome Received a complete response letter from the FDA 2/6/13 Notes: BLA = Biologics license application

San Francisco; member of the Roche Group) and Novartis AG (Basel, Switzerland) Xolair Omalizumab Chronic idiopathic urticaria Phase III data showed it met its primary endpoint 2/26/13 Genzyme Corp. (unit of Sanofi SA; Cambridge, Mass.) Eliglustat tartrate Oral therapy Gaucher disease type 1 Phase III data showed it met the primary endpoints 2/19/13 Relypsa Inc. (Redwood City, Calif.) Patiromer RLY5016

a selective estrogen receptor alpha agonist Advanced prostate cancer Phase II demonstrated significant reductions in their serum-free testosterone levels 2/14/13 ImmunoGen Inc. (Waltham, Mass.) IMGN901 A drug consisting of the company's DM1 cancer cell-killing agent attached to CD56-binding antibody lorvotuzumab Small-cell lung cancer Completed patient enrollment in a Phase II trial 2/13/13 Nektar Therapeutics Inc. (San Francisco) Etirinotecan pegol Etirinotecan pegol Non-small-cell lung cancer

San Francisco) KB002 Precursor chimeric anti-GM-CSF monoclonal antibody to KB003 Persistent asthma Phase I/II data demonstrated preliminary safety, tolerability and signs of activity and support continued development 2/28/13 Cytos Biotechnology Ltd. (Zurich, Switzerland) VLP Virus-like-particle vaccine Allergic asthma Dosed the first patient in a Phase I trial 2/5/13 Okairos AG (Basel, Switzerland) Vaccine Vaccine against RSV Respiratory syncytial virus Started a Phase I trial 2/26/13

Through a spokeswoman, company officials declined to comment on the offering, but it seemed clear that – like other recent financings in the biotech space – the South San Francisco biotech capitalized on its surging stock price

served to delay the scheduled FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting last week, South San Francisco-based Theravance Inc...KaloBios Pharmaceuticals Inc., of South San Francisco, said data from its Phase I/II study of KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) in persistent asthma demonstrated preliminary safety, tolerability and signs of activity and support continued development of humaneered antibody KB003, which is in Phase II testing in severe

Data will be presented this weekend at the American College of Cardiology meeting in San Francisco

That level of efficacy, in a highly refractory population, combined with the drug's favorable safety profile – data were disclosed in January at the T-Cell Lymphoma Forum in San Francisco – further strengthens the drug's commercial credentials, albeit in an indication with a limited patient population

That level of efficacy, in a highly refractory population, combined with the drug's favorable safety profile – data were disclosed in January at the T-Cell Lymphoma Forum in San Francisco – further strengthens the drug's commercial credentials, albeit in an indication with a limited patient population

That level of efficacy, in a highly refractory population, combined with the drug's favorable safety profile – data were disclosed in January at the T-Cell Lymphoma Forum in San Francisco – further strengthens the drug's commercial credentials, albeit in an indication with a limited patient population